NCT00906243View on ClinicalTrials.gov

RNActive®-Derived Therapeutic Vaccine

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Hormone Refractory Prostate Cancer
Interventions
BIOLOGICAL

CV9103

CV9103 encodes for 4 prostate specific antigens.

Trial Locations (1)

32610

University of Florida, College of Medicine, Gainesville

Sponsors

Collaborators (1)

CureVac
All Listed Sponsors
collaborator

CureVac

INDUSTRY

lead

University of Florida

OTHER